Joinn Laboratories (06127) may experience stock price fluctuations as a result of the US FDA's proposed cancellation of animal testing for monoclonal antibodies and other drugs.

Joinn Laboratories (06127) announced that the board of directors has noticed unusual changes in the company's stock price in recent days. After conducting a reasonable inquiry into the relevant circumstances, the board of directors, apart from the disclosures below, confirms that it is not aware of any reasons that may have caused fluctuations in the stock price or trading volume, and is not aware of any insider information that must be disclosed in accordance with Part XIV of the Securities and Futures Ordinance. Recently, the Food and Drug Administration (FDA) of the United States released a plan that may cause fluctuations in the company's stock price, which aims to eliminate animal testing for monoclonal antibodies and other drugs. The company has been deeply involved in non-clinical drug research for thirty years, always keeping pace with industry developments, continuously innovating research and development, and committed to providing customers with high-quality technical services. The company strictly adheres to the "3R" principles of animal experiments, namely "Reduction", "Refinement", and "Replacement", and continues to make efforts in animal experiments and animal welfare. In recent years, the company has focused on and strengthened research on organoids, hoping to replace in vivo animal research with in vitro experiments as soon as possible. The company believes that this plan will be gradually implemented based on solid scientific data research, and will accelerate the pace of research replacement in the industry. This direction is consistent with the company's service mission and development plan. In the future, the company will continue to focus on related research and contribute to the sustainable development of the pharmaceutical research and development field.